Guizhou Sanli Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production, and sales of pharmaceuticals. The products primarily include respiratory medications, tonics, gynecological medications, orthopedic medications, and cardiovascular medications. The specific pharmaceutical products include Kaihoujian Spray (children's version), Kaihoujian Spray, Qijiao Shengbai Capsules, Fuke Zaizao Pills, Zhike Huatan Pills, Huangqi Granules, and Qiangli Tianma Duzhong Capsules. The Company distributes its products within the domestic market.

Employees

1,887

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-06-12	14.95 ¥	-3.36%	15,449,400
26-06-11	15.47 ¥	+4.74%	19,635,710
26-06-10	14.77 ¥	-3.21%	13,585,700
26-06-09	15.26 ¥	-5.22%	26,127,102
26-06-08	16.10 ¥	-5.29%	23,502,700

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2026-06-12			5-day change	1st Jan Change
14.95 ^CNY	-3.36%		-5.56%	+27.78%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE

Market Cap	6.05B 894M 772M 712M 666M 1.25B 84.99B 1.27B 8.4B 3.28B 41.37B 3.36B 3.28B 143B	P/E Ratio 2024	19.4x	P/E Ratio 2025	106x
Enterprise Value	6.4B 946M 817M 753M 705M 1.32B 89.89B 1.34B 8.89B 3.47B 43.75B 3.55B 3.47B 151B	EV / Sales 2024	2.48x	EV / Sales 2025	2.99x
Free-Float	40.74%	Yield 2024	2.62%	Yield 2025	0.51%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE
05-24	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 700 million in funding	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 300 million in funding	CI
12-03	Sanli Pharma to Withdraw Stake in Associate; Shares Down 3%	MT
25-10-27	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-09-12	Tranche Update on Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on September 13, 2024.	CI
25-09-10	Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback announced on September 12, 2024, has closed with 7,869,300 shares, representing 1.93% for CNY 99.95 million.	CI
25-08-27	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-04-22	Guizhou Sanli Pharmaceutical Co.,Ltd announces Annual dividend, payable on June 26, 2025	CI
25-04-22	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

1 day	-3.36%
1 week	-5.56%
Current month	-8.17%
1 month	+24.90%
3 months	+27.89%
6 months	+23.66%
Current year	+27.78%

GuiZhou SanLi Pharmaceutical Co.,Ltd Stock

Stocks

603439

CNE1000040B4

Pharmaceuticals

Valuation: GuiZhou SanLi Pharmaceutical Co.,Ltd

Chart: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest news : GuiZhou SanLi Pharmaceutical Co.,Ltd

Quotes and Performance

Course Extremes

Managers and Directors: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	14.18	16.64
1 month	11.88	17.46
Current year	10.49	17.46
1 year	10.49	17.46
3 years	10.49	20.34
5 years	10.49	21.28
10 years	8.82	44.1

Manager	Title	Age	Since
Qian Fan Zhang CEO	Chief Executive Officer	41	2024-05-26
Hai Zhang CEO	Chief Executive Officer	41	2011-08-31
Ke Guo DFI	Director of Finance/CFO	39	2024-10-31

Director	Title	Age	Since
Hai Zhang CHM	Chairman	41	2018-02-28
Qian Fan Zhang BRD	Director/Board Member	41	2018-02-28
Yong Jian Sheng BRD	Director/Board Member	52	2015-01-27

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-09-10	Hai Zhang	Sell	Chief Executive Officer	21,000,000	5.1428%
24-08-01	Jue Ben Wang	Buy	Director	13,000	0.0032%
23-08-04	Yuan Yu	Sell		25,000	0.0061%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU SANLI PHARMACEUTICAL CO.,LTD	-3.36%	-5.56%	+21.15%	-11.59%	924M
ELI LILLY AND COMPANY	-2.41%	+0.14%	+39.53%	+154.43%	1,035B
JOHNSON & JOHNSON	+1.07%	+3.48%	+53.75%	+50.64%	574B
ABBVIE INC.	+1.32%	+0.22%	+18.35%	+65.35%	397B
ROCHE HOLDING AG	+0.77%	+0.77%	+21.19%	+15.95%	324B
ASTRAZENECA PLC	-0.85%	-0.68%	+23.44%	+14.94%	281B
NOVARTIS AG	+0.44%	+5.39%	+25.86%	+35.39%	278B
NOVO NORDISK A/S	+1.66%	+1.20%	-44.41%	-47.37%	193B
AMGEN INC.	+0.32%	+1.61%	+19.48%	+63.42%	191B
GILEAD SCIENCES, INC.	-0.22%	-2.76%	+12.08%	+61.30%	156B
Average	-0.47%	+0.02%	+19.04%	+40.25%	343.09B
Weighted average by Cap.	-0.74%	+1.04%	+28.20%	+71.89%

	2024	2025
Net sales	2.14B 317M 274M 252M 236M 442M 30.12B 449M 2.98B 1.16B 14.66B 1.19B 1.16B 50.76B	1.7B 252M 217M 200M 187M 351M 23.92B 357M 2.36B 922M 11.64B 944M 924M 40.31B
Net income	274M 40.49M 34.98M 32.23M 30.17M 56.54M 3.85B 57.41M 381M 148M 1.87B 152M 149M 6.49B	46.25M 6.84M 5.9M 5.44M 5.09M 9.54M 650M 9.69M 64.24M 25.05M 316M 25.65M 25.11M 1.09B
Net Debt	108M 15.91M 13.74M 12.66M 11.85M 22.21M 1.51B 22.56M 150M 58.3M 736M 59.71M 58.44M 2.55B	349M 51.53M 44.51M 41.01M 38.39M 71.95M 4.9B 73.06M 484M 189M 2.38B 193M 189M 8.25B